Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.21), FiscalAI reports. The firm had revenue of $21.48 million for the quarter, compared to the consensus estimate of $20.39 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.
Capstone Therapeutics Stock Performance
Capstone Therapeutics stock traded down $0.09 during mid-day trading on Wednesday, hitting $0.22. 9,018,864 shares of the company’s stock traded hands, compared to its average volume of 1,896,040. The company has a quick ratio of 0.29, a current ratio of 0.95 and a debt-to-equity ratio of 0.79. Capstone Therapeutics has a one year low of $0.21 and a one year high of $2.07. The firm has a 50 day moving average price of $0.27 and a 200 day moving average price of $0.44. The company has a market cap of $3.41 million, a PE ratio of -0.07 and a beta of -1.52.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Capstone Therapeutics
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Featured Stories
- Five stocks we like better than Capstone Therapeutics
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
- Visa’s AI Opportunity Is Hiding in Every Transaction
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
